[{"id":"9f8d313e-74c9-44df-85b7-d0e225eab089","acronym":"KEYSTEP-008","url":"https://clinicaltrials.gov/study/NCT04895722","created_at":"2021-05-20T11:54:07.770Z","updated_at":"2024-07-02T16:34:59.923Z","phase":"Phase 2","brief_title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","source_id_and_acronym":"NCT04895722 - KEYSTEP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4830 • favezelimab/pembrolizumab (MK-4280A) • quavonlimab/pembrolizumab (MK-1308A) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 06/25/2021","start_date":" 06/25/2021","primary_txt":" Primary completion: 10/20/2025","primary_completion_date":" 10/20/2025","study_txt":" Completion: 11/18/2025","study_completion_date":" 11/18/2025","last_update_posted":"2024-05-30"},{"id":"ae764849-22a9-4b59-9c96-821255ae4097","acronym":"MK-4830-001","url":"https://clinicaltrials.gov/study/NCT03564691","created_at":"2021-01-18T17:33:06.094Z","updated_at":"2024-07-02T16:35:02.929Z","phase":"Phase 1","brief_title":"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)","source_id_and_acronym":"NCT03564691 - MK-4830-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • Lenvima (lenvatinib) • pemetrexed • MK-4830"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 442","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 09/28/2025","primary_completion_date":" 09/28/2025","study_txt":" Completion: 09/28/2025","study_completion_date":" 09/28/2025","last_update_posted":"2024-05-17"},{"id":"ce6acbdf-d0c9-46e4-a247-444e713619ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413095","created_at":"2024-05-18T04:21:47.057Z","updated_at":"2025-02-25T16:02:48.188Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","source_id_and_acronym":"NCT06413095","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • IFNG • CD163 • GZMB","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD163 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 06/22/2023","study_completion_date":" 06/22/2023","last_update_posted":"2024-05-14"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"a773610b-43c7-4cf0-b3a9-805cd9684517","acronym":"KEYMAKER-U01B","url":"https://clinicaltrials.gov/study/NCT04165083","created_at":"2021-01-18T20:19:29.647Z","updated_at":"2024-07-02T16:35:19.534Z","phase":"Phase 2","brief_title":"KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)","source_id_and_acronym":"NCT04165083 - KEYMAKER-U01B","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 09/17/2025","primary_completion_date":" 09/17/2025","study_txt":" Completion: 09/17/2025","study_completion_date":" 09/17/2025","last_update_posted":"2024-02-13"}]